Skip to main content
Journal ArticleOPEN ACCESS

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma

  • Andersen R
  • Donia M
  • Borch T
  • et al.
Journal for ImmunoTherapy of Cancer (2014) 2(S3)
DOI: 10.1186/2051-1426-2-s3-p1
N/ACitations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Meeting abstracts Adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TILs) achieved impressive clinical results in several single institution Phase I/II clinical trials performed outside of Europe, and holds the promise to enter the mainstream of standard melanoma care in the near

Cite

CITATION STYLE

APA

Andersen, R., Donia, M., Borch, T. H., Steensgaard, E. E., Iversen, T. Z., Kongsted, P., … Svane, I. M. (2014). Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma. Journal for ImmunoTherapy of Cancer, 2(S3). https://doi.org/10.1186/2051-1426-2-s3-p1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free